文献速递生殖医学

常规非整倍体植入前遗传学检测中筛查≤5 Mb节段性非整倍体的必要性评估

Assessing the necessity of screening ≤5 Mb segmental aneuploidy in routine PGT for aneuploidies.
PubMed 文献 · Reprod Biomed Online · 2024-04-11

这项回顾性研究分析了2019至2023年间346对夫妇的963份滋养层活检样本,报告了≥1 Mb的节段性非整倍体。≤5 Mb节段性非整倍体发生率为2.3%(22/963),其中新发者占63.6%(14/22),新发者中致病/可能致病拷贝数变异占50.0%(7/14),占全部囊胚的0.7%。作者认为常规临床实践中无需将PGT-A分辨率提高至5 Mb。

要点

  • 囊胚节段性非整倍体发生率为15.1%(145/963),≤5 Mb者仅占2.3%(22/963)。
  • ≤5 Mb节段性非整倍体中新发者占63.6%(14/22),其中致病/可能致病拷贝数变异占50.0%(7/14)。
  • 作者认为常规PGT-A无需将分辨率提高至5 Mb。

核心结论

  • 人类囊胚中致病/可能致病的≤5 Mb新发节段性非整倍体发生率极低,常规临床实践中没有迫切需求将PGT-A分辨率提高至5 Mb。

研究设计与样本

  • 回顾性研究,分析2019至2023年间346对夫妇接受PGT的963份滋养层活检样本,报告≥1 Mb的节段性非整倍体。

主要发现

  • 囊胚节段性非整倍体发生率为15.1%(145/963),其中≤5 Mb节段性非整倍体占2.3%(22/963)。
  • ≤5 Mb节段性非整倍体更多见于染色体q臂而非p臂;缺失比重复更常见,缺失17例 vs 重复5例。
  • ≤5 Mb节段性非整倍体中新发者占63.6%(14/22),新发者中致病/可能致病拷贝数变异占50.0%(7/14),占963枚囊胚的0.7%。
  • 对携带≤5 Mb节段性非整倍体的囊胚,备份活检样本再分析显示35.7%的新发节段性非整倍体(5/14)在备份样本中未检出。
  • 有病例报告显示产前诊断(羊膜腔穿刺)未发现囊胚期检出的胚胎≤5 Mb节段性非整倍体。

临床怎么用

  • 作者认为常规临床实践无需将PGT-A分辨率提高至5 Mb。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RESEARCH QUESTION: Does routine clinical practice require an increase in the resolution of preimplantation genetic testing for aneuploidies (PGT-A) to detect segmental aneuploidies ≤5 Mb? DESIGN: This retrospective study analysed 963 trophectoderm biopsies from 346 couples undergoing PGT between 2019 and 2023. Segmental aneuploidies ≥1 Mb were reported. The characteristics, clinical interpretation and concordance of segmental aneuploidies ≤5 Mb were analysed. RESULTS: The incidence of segmental aneuploidies was 15.1% (145/963) in blastocysts, with segmental aneuploidies of ≤5 Mb accounting for 2.3% (22/963). The size of the segmental aneuploidies showed a skewed distribution. Segmental aneuploidies ≤5 Mb were found to occur more frequently on the q arm of the chromosome, compared with the p arm. Losses of ≤5 Mb segmental aneuploidies were more prevalent than gains, with 17 deletions compared with 5 duplications. Of the segmental aneuploidies, 63.6% (14/22) ≤5 Mb were de novo, and 50.0% (7/14) of de-novo segmental aneuploidies were pathogenic/likely pathogenic (P/LP) copy number variations, accounting for 0.7% of 963 blastocysts. For blastocysts carrying ≤5 Mb segmental aneuploidies, a re-analysis of back-up biopsy samples showed that 35.7% of de-novo segmental aneuploidies (5/14) were not detected in the back-up samples. Cases were reported in which prenatal diagnosis (amniocentesis) revealed the absence of embryonic ≤5 Mb segmental aneuploidies detected at the blastocyst stage. CONCLUSIONS: The incidence of P/LP de-novo ≤5 Mb segmental aneuploidies in human blastocysts is extremely low. There is no compelling need to increase the resolution of PGT-A to 5 Mb in routine clinical practice.

来源:Reprod Biomed Online,查看原文。版权归原作者所有。

引用

  1. Zhang J, Qin M, Ma M, et al. Assessing the necessity of screening ≤5 Mb segmental aneuploidy in routine PGT for aneuploidies. Reprod Biomed Online. 2024. PMID: 38936339. doi:10.1016/j.rbmo.2024.103991

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。